CureVac
Desconocido
Inno4Vac: Innovations to accelerate vaccine development and manufacture
CUREVAC AG
participó en un
H2020:
H2020-JTI-IMI2-2020-20-two-stage
Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado
2021-07-19 - 2027-02-28 | Financiado
HEPAVAC: Cancer Vaccine development for Hepatocellular Carcinoma
CUREVAC AG
participó en un
FP7:
"Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given t...
Financiado
Financiado
* No se disponen de datos de la empresa actual.